首页> 美国卫生研究院文献>Human Vaccines Immunotherapeutics >Meningococcal serogroup B disease in Turkey
【2h】

Meningococcal serogroup B disease in Turkey

机译:土耳其的脑膜炎球菌B群血清疾病

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Each country chooses the appropriate vaccine against IMD depending on the locally prevalent serogroups of N. meningitides. Frequency of each meningococcal serogroup varies considerably over time and by geographical location. Despite the majority of IMD cases (85%) are caused by serogroups B and C in Europe, true prevalence of serogroup B IMD cases in Turkey is unclear. In one of the recent studies, the sharp decrease of serogroup B IMD from 35% down to 2.5% in a few years despite the absence of vaccination is confusing. Millions of European Turkish people travels from Europe to Turkey every year who could most probably carry serogroup B. It is obvious that a nationwide active surveillance is crucial to assess the the true epidemiology and burden of IMD which has a major impact on the choice of vaccine type and age interval the vaccination to be implemented.
机译:每个国家根据脑膜炎奈瑟氏球菌的本地流行血清群选择合适的IMD疫苗。每个脑膜炎球菌血清群的频率随时间和地理位置的不同而有很大差异。尽管在欧洲,大多数IMD病例(85%)是由B和C血清群引起的,但土耳其B血清型IMD病例的真正流行率尚不清楚。在最近的一项研究中,尽管没有接种疫苗,但B组血清IMD在3年内从35%急剧下降到2.5%仍然令人困惑。每年都有数百万欧洲土耳其人从欧洲前往土耳其,他们很可能携带B群。很明显,全国范围内的主动监视对于评估IMD的真正流行病学和负担至关重要,这对疫苗的选择具有重要影响疫苗的类型和年龄间隔。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号